{"id":393249,"date":"2020-12-03T17:04:04","date_gmt":"2020-12-03T22:04:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=393249"},"modified":"2020-12-03T17:04:04","modified_gmt":"2020-12-03T22:04:04","slug":"florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/","title":{"rendered":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease"},"content":{"rendered":"

\nStudy demonstrates the use of a wearable device in treatment of Parkinson\u2019s disease resulted in significant improvement in patient outcomes compared to\u00a0standard of care management
\n<\/h2>\n
\n

MINNEAPOLIS and MELBOURNE, Australia, Dec. 03, 2020 (GLOBE NEWSWIRE) — The Florey Institute and Global Kinetics Pty Ltd. today announced that data from a new clinical study of the FDA-cleared wearable Personal KinetiGraph\u00ae<\/sup> (PKG\u00ae<\/sup>) has been published in the Nature Partners Journal <\/em>–<\/em> Parkinson\u2019s Disease<\/em> (npj<\/em> \u2013 Parkinson\u2019s Disease)<\/em>.<\/p>\n

The study entitled \u201cA controlled trial of objective measurement to guide therapy improves outcomes in Parkinson\u2019s disease\u201d adds to the body of evidence showing the advantages of using a wearable, continuous objective measurement system in the monitoring and management of motor symptoms affecting people with Parkinson\u2019s disease (PD).<\/p>\n

This controlled study compared the outcomes of routine clinical management to clinical management aided by the PKG in 200 participants. Individuals whose management was aided by the PKG underwent medication adjustments with the aim of getting them into an objective PKG-based \u2018target range\u2019. In the control arm, optimization of therapy was judged using usual clinical practice. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS), a common measurement of PD outcomes, was used as the primary endpoint of the study. The PKG treatment arm had a significant improvement of 8.5 points (p=0.001) on the UPDRS at the last visit compared to their baseline, and the group managed with the aid of PKG improved by 6.3 points (p=0.02) more than the standard of care arm.<\/p>\n

Other measures of how patients experience PD symptoms improved in the treatment group where clinicians had access to objective data in the PKG. These measures include the UPDRS III which is the motor component of the UPDRS rating scale, the PDQ-39 which is a patient-reported survey of how often people affected by PD experience difficulties across 8 dimensions of daily living including relationships, social situations and communication and the Severity of Non-dopaminergic Symptoms in Parkinson\u2019s Disease (SENS-PD) scale measuring non-motor symptoms in PD.<\/p>\n\n\n\n\n\n\n
\u00a0<\/td>\nTreatment
(Mean \u00b1 StD)<\/td>\n		Standard of Care
(Mean \u00b1 StD)<\/td>\n		P-value*<\/td>\n<\/tr>\n
UPDRS III<\/td>\n28.6\u00b1 8.0<\/td>\n33.2 \u00b110.0<\/td>\n0.002<\/td>\n<\/tr>\n
PDQ-39<\/td>\n22.2\u00b1 13.6<\/td>\n25.6 \u00b118.8<\/td>\n0.21<\/td>\n<\/tr>\n
SENS PD<\/td>\n9.9 \u00b14.6<\/td>\n11.4\u00b1 4.9<\/td>\n0.055<\/td>\n<\/tr>\n
\n *Smaller p-values are indicative of higher significance<\/sup>\n <\/td>\n<\/tr>\n<\/table>\n

Professor Malcolm Horne, Movement Disorder Specialist and an author on the study report, said, \u201cThis study provides evidence that objective measurement and targets can improve clinical outcomes for people with Parkinson\u2019s disease.\u00a0 Many clinicians around the world use the PKG to guide their treatment of Parkinson\u2019s.\u00a0Introducing PKG targets may, in time, enable other clinicians and nurses to treat people with Parkinson\u2019s disease through the lens of objective measurement.\u201d<\/p>\n

Mark Frasier, PhD, Senior Vice President of Research Programs at The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF), which funded part of the study, added, \u201cThese findings further confirm the need for objective measures of Parkinson\u2019s to more optimally manage symptoms and to evaluate disease and the impact of interventions in research studies. \u00a0These results could also serve development of an enhanced care model, where continuous symptom monitoring could enable more efficient and tailored treatments.\u201d<\/p>\n

The study was supported by grants from MJFF, Parkinson\u2019s Victoria, Shake it Up Australia, and an in-kind grant from Global Kinetics.<\/p>\n

\n About Global Kinetics <\/strong>
\n Pty<\/strong>
\n Ltd.<\/strong>
\n
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson\u2019s disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph\u00a0(PKG). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson\u2019s. To date, Global Kinetics has supported clinical decisions for doctors who have treated more than 30,000 patients with Parkinson\u2019s disease, generating more than 7,200,000 hours of clinical data from the FDA-cleared, CE-marked PKG wearable system. Global Kinetics is a privately held company, headquartered in Melbourne, Australia with offices in London, UK, and Minneapolis, MN.<\/p>\n

For more information, visit: www.pkgcare.com<\/a>
Follow our LinkedIn updates: https:\/\/www.linkedin.com\/company\/globalkineticscorp<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Global Kinetics Pty Ltd<\/p>\n

Karen Krygier
Director Clinical Research<\/p>\n

Mobile: +1.612.240.2437<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Study demonstrates the use of a wearable device in treatment of Parkinson\u2019s disease resulted in significant improvement in patient outcomes compared to\u00a0standard of care management MINNEAPOLIS and MELBOURNE, Australia, Dec. 03, 2020 (GLOBE NEWSWIRE) — The Florey Institute and Global Kinetics Pty Ltd. today announced that data from a new clinical study of the FDA-cleared wearable Personal KinetiGraph\u00ae (PKG\u00ae) has been published in the Nature Partners Journal – Parkinson\u2019s Disease (npj \u2013 Parkinson\u2019s Disease). The study entitled \u201cA controlled trial of objective measurement to guide therapy improves outcomes in Parkinson\u2019s disease\u201d adds to the body of evidence showing the advantages of using a wearable, continuous objective measurement system in the monitoring and management of motor symptoms affecting people with Parkinson\u2019s … <\/p>\n

Continue reading “Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-393249","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFlorey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Study demonstrates the use of a wearable device in treatment of Parkinson\u2019s disease resulted in significant improvement in patient outcomes compared to\u00a0standard of care management MINNEAPOLIS and MELBOURNE, Australia, Dec. 03, 2020 (GLOBE NEWSWIRE) — The Florey Institute and Global Kinetics Pty Ltd. today announced that data from a new clinical study of the FDA-cleared wearable Personal KinetiGraph\u00ae (PKG\u00ae) has been published in the Nature Partners Journal – Parkinson\u2019s Disease (npj \u2013 Parkinson\u2019s Disease). The study entitled \u201cA controlled trial of objective measurement to guide therapy improves outcomes in Parkinson\u2019s disease\u201d adds to the body of evidence showing the advantages of using a wearable, continuous objective measurement system in the monitoring and management of motor symptoms affecting people with Parkinson\u2019s … Continue reading "Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T22:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease\",\"datePublished\":\"2020-12-03T22:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/\"},\"wordCount\":679,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/\",\"name\":\"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=\",\"datePublished\":\"2020-12-03T22:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/","og_locale":"en_US","og_type":"article","og_title":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk","og_description":"Study demonstrates the use of a wearable device in treatment of Parkinson\u2019s disease resulted in significant improvement in patient outcomes compared to\u00a0standard of care management MINNEAPOLIS and MELBOURNE, Australia, Dec. 03, 2020 (GLOBE NEWSWIRE) — The Florey Institute and Global Kinetics Pty Ltd. today announced that data from a new clinical study of the FDA-cleared wearable Personal KinetiGraph\u00ae (PKG\u00ae) has been published in the Nature Partners Journal – Parkinson\u2019s Disease (npj \u2013 Parkinson\u2019s Disease). The study entitled \u201cA controlled trial of objective measurement to guide therapy improves outcomes in Parkinson\u2019s disease\u201d adds to the body of evidence showing the advantages of using a wearable, continuous objective measurement system in the monitoring and management of motor symptoms affecting people with Parkinson\u2019s … Continue reading \"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T22:04:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease","datePublished":"2020-12-03T22:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/"},"wordCount":679,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/","name":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=","datePublished":"2020-12-03T22:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjYwMSMzODU1ODc1IzIxOTM4Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/florey-institute-and-global-kinetics-announce-results-from-randomized-clinical-trial-of-the-personal-kinetigraph-pkg-in-persons-with-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Florey Institute and Global Kinetics Announce Results from Randomized Clinical Trial of the Personal KinetiGraph\u00ae (PKG\u00ae) in Persons with Parkinson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=393249"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=393249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=393249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=393249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}